基托和基托-寡糖类作为代谢功能障碍相关的脂肪性肝病 (MASLD) 的多功能治疗药物
Gaoli Zhou1, Ronge Xing2, Zongji Wang3
1Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, 266000, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Carbohydrate polymers
|December 31, 2025
概括
基托和基托-寡糖化合物对治疗与代谢功能障碍相关的脂肪性肝病 (MASLD) 有前途. 这些化合物向多种途径,改善肠道健康和肝脏脂质代谢,以潜在的治疗用途.
科学领域:
- 生物化学 生物化学
- 肝病学 肝病学是一种肝病学.
- 微生物学 微生物学
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益严重的全球健康问题.
- 目前用于MASLD的治疗方法的有效性和安全性概况有限.
- 迫切需要替代治疗策略.
研究的目的:
- 评估基托和基托-寡糖糖类作为MASLD治疗剂的潜力.
- 研究这些化合物的保护作用背后的机制.
主要方法:
- 审查细胞,动物和初步临床研究.
- 对肠道屏障功能和微生物群组成的影响分析.
- 对关键代谢和炎症信号通路 (AMPK,PPARα,Nrf2,NF-κB) 的影响评估.
主要成果:
- 奇托和奇托-寡糖增强肠道屏障的完整性,调节肠道微生物群.
- 这些化合物减少了脂多糖转位和肝炎的发生.
- 它们激活有益的信号通路 (AMPK,PPARα,Nrf2) 并抑制有害的信号通路 (脂质生成,NF-κB),恢复脂质稳态并减少氧化应激.
结论:
- 奇托和奇托-寡糖化合物显示出对MASLD的多方面的治疗潜力.
- 它们能够准多种病理生理路径的能力为管理肝病提供了一种可持续的方法.
- 需要进一步的临床研究来确认MASLD患者的疗效和安全性.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Chronic Pancreatitis II: Collaborative Care
284
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
284
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
153
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
153
Drugs for Treatment of Constipation-Predominant IBS
670
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
670


